ThromboGenics raises €77.8m to build for US ocriplasmin launch
This article was originally published in Scrip
Executive Summary
ThromboGenics has raised €77.8 million through a private placement via an accelerated bookbuilding procedure announced yesterday after the market closed. The funds will be used to build US commercial operations for the ophthalmic drug candidate ocriplasmin, recently the subject of a deal with Alcon over ex-US rights.